» Articles » PMID: 17187428

Hepatitis B Virus Promotes Hepatocarcinogenesis in Transgenic Mice

Overview
Journal Hepatology
Specialty Gastroenterology
Date 2006 Dec 26
PMID 17187428
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: HBV is a major risk factor for hepatocellular carcinoma (HCC). However, whether HBV can directly cause HCC or only indirectly via the induction of chronic liver inflammation has been controversial. By using transgenic mice carrying the entire HBV genome as a model, we now demonstrate that HBV by itself is an inefficient carcinogen. However, it can efficiently promote hepatocarcinogenesis initiated by the carcinogen diethylnitrosamine (DEN). This effect of HBV does not involve chronic liver inflammation, is apparently due to enhanced hepatocellular apoptosis and compensatory regeneration following DEN treatment, and does not require the HBV X protein.

Conclusion: Our results demonstrate a direct role of HBV in a hepatocarcinogenesis pathway that involves the interaction between this virus and a dietary carcinogen.

Citing Articles

Viral Oncogenesis: Synergistic Role of Genome Integration and Persistence.

La Frazia S, Pauciullo S, Zulian V, Garbuglia A Viruses. 2025; 16(12.

PMID: 39772271 PMC: 11728759. DOI: 10.3390/v16121965.


Resistance to Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma (HCC): Clinical Implications and Potential Strategies to Overcome the Resistance.

Gawi Ermi A, Sarkar D Cancers (Basel). 2024; 16(23).

PMID: 39682130 PMC: 11640171. DOI: 10.3390/cancers16233944.


Preclinical Models of Hepatocellular Carcinoma: Current Utility, Limitations, and Challenges.

Cigliano A, Liao W, Deiana G, Rizzo D, Chen X, Calvisi D Biomedicines. 2024; 12(7).

PMID: 39062197 PMC: 11274649. DOI: 10.3390/biomedicines12071624.


Effects of Hayata juice on high-fat diet-induced obesity in HBV transgenic mice.

Chu P, Hsu C, Lin Y, Pan Y, Dai Y, Yu Y Heliyon. 2024; 10(2):e24438.

PMID: 38312542 PMC: 10835261. DOI: 10.1016/j.heliyon.2024.e24438.


Linoleate-pazopanib conjugation as active pharmacological ingredient to abolish hepatocellular carcinoma growth.

Wang K, Liao P, Chang W, Yang C, Su Y, Wu P Front Pharmacol. 2024; 14:1281067.

PMID: 38293667 PMC: 10824963. DOI: 10.3389/fphar.2023.1281067.